Data gathered: November 21
AI Stock Analysis - AbbVie (ABBV)
Analysis generated August 20, 2024. Powered by Chat GPT.
AbbVie Inc. (ABBV) is a global, research-based biopharmaceutical company that engages in the development and marketing of advanced therapies primarily for the treatment of chronic illnesses and complex medical conditions. Since its inception as a spin-off from Abbott Laboratories in 2013, AbbVie has focused on immunology, oncology, virology, and neurology sectors. The company is well known for its flagship product, Humira, which has been one of the best-selling drugs globally. Additionally, AbbVie has fortified its portfolio through acquisitions, most notably the $63 billion purchase of Allergan in 2020, enhancing its capabilities in eye care and aesthetics.
Stock Alerts - AbbVie (ABBV)
 |
AbbVie | November 12 Ro Khanna (member of U.S. congress) is buying shares |
|
AbbVie | November 11 Price is down by -10.7% in the last 24h. |
|
AbbVie | October 30 Price is up by 6.2% in the last 24h. |
|
AbbVie | October 29 News Alert: AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline |
Alternative Data for AbbVie
About AbbVie
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
| Price | $167.76 |
| Target Price | Sign up |
| Volume | 6,240,000 |
| Market Cap | $294B |
| Year Range | $152.15 - $203.87 |
| Dividend Yield | 3.94% |
| PE Ratio | 58.04 |
| Analyst Rating | 65% buy |
| Industry | Drug Manufacturers |
In the news
 |
AbbVie (NYSE:ABBV) Given New $195.00 Price Target at Wells Fargo & CompanyNovember 21 - ETF Daily News |
AbbVie Inc. stock outperforms competitors on strong trading dayNovember 20 - MarketWatch |
|
 |
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?November 19 - Yahoo |
AbbVie Inc. stock rises Tuesday, still underperforms marketNovember 19 - MarketWatch |
|
 |
Where Will AbbVie Be in 5 Years?November 18 - Yahoo |
AbbVie Receives European Commission Approval of ELAHERE for the Treatment of Platinum-Resistant Ovarian CancerNovember 18 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 14.5B | 10.3B | 4.14B | 1.56B | 4.7B | 3.000 |
| Q2 '24 | 14.5B | 9.48B | 4.98B | 1.37B | 4.77B | 2.650 |
| Q1 '24 | 12.3B | 9.31B | 3B | 1.37B | 4.31B | 2.310 |
| Q4 '23 | 14.3B | 5.7B | 8.6B | 822M | 3.62B | 2.790 |
| Q3 '23 | 13.9B | 11.9B | 2.07B | 1.78B | 4.51B | 2.950 |
Insider Transactions View All
| GONZALEZ RICHARD A filed to sell 446,599 shares at $186.5. August 7 '24 |
| GONZALEZ RICHARD A filed to sell 513,099 shares at $175. July 19 '24 |
| Donoghoe Nicholas filed to sell 55,903 shares at $176.3. March 22 '24 |
| Stewart Jeffrey Ryan filed to sell 88,681 shares at $179. March 20 '24 |
| Stewart Jeffrey Ryan filed to sell 93,780 shares at $178.9. March 20 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$153.11 0% | 46 |
 |
Eli Lilly and CompanyLLY |
$753.41 0% | 62 |
 |
PfizerPFE |
$24.94 0% | 45 |
 |
AstrazenecaAZN |
$63.2 0% | 68 |
 |
TherapeuticsMDTXMD |
$1.34 0% | 39 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Nov 11, 24 | Buy | $1K - $15K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
| Kathy Manning |
Aug 16, 24 | Buy | $1K - $15K |
Read more about AbbVie (ABBV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of AbbVie?
The Market Cap of AbbVie is $294B.
What is AbbVie's PE Ratio?
As of today, AbbVie's PE (Price to Earnings) ratio is 58.04.
What is the current stock price of AbbVie?
Currently, the price of one share of AbbVie stock is $167.76.
How can I analyze the ABBV stock price chart for investment decisions?
The ABBV stock price chart above provides a comprehensive visual representation of AbbVie's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling AbbVie shares. Our platform offers an up-to-date ABBV stock price chart, along with technical data analysis and alternative data insights.
Does ABBV offer dividends to its shareholders?
Yes, AbbVie (ABBV) offers dividends to its shareholders, with a dividend yield of 3.94%. This dividend yield represents AbbVie's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering AbbVie in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of AbbVie?
Some of the similar stocks of AbbVie are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and TherapeuticsMD.
.